Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries

Thursday, June 25, 2020   (0 Comments)
Posted by: Alisha Brown
Share |

THOUSAND OAKS, Calif.June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.  Amgen acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla® (apremilast) from Celgene in 2019. AMG 634 is currently in Phase 2 studies led by The Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study).

"AMG 634 could have potential for patients suffering from ENL and TB, two diseases that continue to challenge many countries around the world," said  David M. Reese , M.D. executive vice president of Research and Development at Amgen. "We believe that the right organization focused on global health will be able to help further develop the molecule and get it directly into the hands of those patients in need of treatment options."

Approximately 225,000 new cases of leprosy are identified every year1, and a significant number of leprosy patients suffer from ENL, an autoimmune complication that can occur many years after being cured of leprosy and can cause permanent nerve damage and disability2. Tuberculosis affects 10.4 million patients every year and causes over one million deaths. Current treatments are often inadequate and can leave patients with permanent, clinically significant lung damage3.

While intending to support the two Phase 2 clinical trials in ENL and TB set to begin in 2021 by providing study drug, Amgen is interested in partnering these programs with a non-government organization (NGO) for further development. 

More information about the clinical trial in ENL can be found here and in TB can be found here.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit and follow us on

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including Adaptive Biotechnologies (including statements regarding such collaboration's ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19), BeiGene, Ltd., or the Otezla acquisition, including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

CONTACT: Amgen, Thousand Oaks
Megan Fox , 805-447-1423 (media)
Trish Rowland , 805-447-5631 (media)
Arvind Sood , 805-447-1060 (investors)

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal